• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Leung Gabriel sold $17,297 worth of Ordinary Shares (999 units at $17.31), decreasing direct ownership by 1% to 81,229 units (SEC Form 4)

    6/4/25 4:24:53 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care
    Get the next $NVCR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    LEUNG GABRIEL

    (Last) (First) (Middle)
    C/O NOVOCURE INC.
    1550 LIBERTY RIDGE DRIVE, SUITE 115

    (Street)
    WAYNE PA 19087

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NovoCure Ltd [ NVCR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares 06/03/2025 S 999(1) D $17.3146(2) 81,229(3) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
    2. This transaction was executed in multiple trades at prices ranging from $17.1025 USD to $17.50 USD; the price reported above reflects the weighted average sale price.
    3. Amended total to correct prior mathematical error.
    Remarks:
    Steven Robbins, as attorney in fact for Leung, Gabriel 06/04/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NVCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVCR

    DatePrice TargetRatingAnalyst
    12/2/2024$18.00 → $30.00In-line → Outperform
    Evercore ISI
    10/16/2024$24.00 → $30.00Neutral → Buy
    H.C. Wainwright
    11/20/2023$15.00Neutral
    JP Morgan
    8/28/2023$85.00 → $25.00Buy → Neutral
    H.C. Wainwright
    8/8/2023$45.00Neutral → Overweight
    Piper Sandler
    8/4/2023$51.00Outperform
    SVB Securities
    7/31/2023$33.00Underperform → In-line
    Evercore ISI
    6/7/2023$53.00 → $46.00Underperform → Neutral
    Wedbush
    More analyst ratings

    $NVCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

      TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free survival, a key outcome for patients with pancreatic cancer Results from PANOVA-3 accepted as a late-breaking abstract for oral presentation at ASCO and simultaneous publication in the Journal of Clinical Oncology Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) and Novocure (NASDAQ:NVCR)

      5/31/25 3:08:00 PM ET
      $NVCR
      $ZLAB
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

      TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free survival, a key outcome for patients with pancreatic cancer Results from PANOVA-3 accepted as a late-breaking abstract for oral presentation at ASCO and simultaneous publication in the Journal of Clinical Oncology Novocure (NASDAQ:NVCR) announced that results from the Phase 3 PANOVA-3 tr

      5/31/25 8:00:00 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • Novocure Announces Upcoming Investor Events

      Novocure (NASDAQ:NVCR) announced today that management will participate in two upcoming investor events. PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31 at 8:00 p.m. ET / 7:00 p.m. CT in Chicago to review data from the successful Phase 3 PANOVA-3 clinical trial in unresectable, locally advanced pancreatic cancer. Novocure leadership will be joined by Vincent Picozzi, MD, MMM, medical oncologist and investigator in the PANOVA-3 trial, to review the results and address questions. To request in-person attendance, please contact investor relations at [email protected]. Jefferies Global Healthcare Conference, June 4, 2025: Ashley Cordova, Chi

      5/27/25 7:00:00 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care

    $NVCR
    Financials

    Live finance-specific insights

    See more
    • Novocure Reports First Quarter 2025 Financial Results

      Quarterly net revenues of $155 million, up 12% year-over-year, with 4,268 active patients on therapy as of March 31, 2025 Results from Phase 3 PANOVA-3 trial in pancreatic cancer accepted as late-breaking abstract for presentation at 2025 American Society of Clinical Oncology Annual Meeting CE Mark approval received for Optune Lua for use concurrently with immune checkpoint inhibitor or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen Novocure (NASDAQ:NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive for

      4/24/25 7:00:00 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • Novocure to Report First Quarter 2025 Financial Results

      Novocure (NASDAQ:NVCR) will report financial results for the first quarter 2025 on April 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 24, to discuss the company's financial results for the three-month quarter that ended March 31, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure's website, www.novocure.com/investor-

      4/1/25 7:00:00 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

      Full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Optune Lua® received FDA approval for the treatment of metastatic non-small cell lung cancer, commercial rollout underway in the U.S. Phase 3 PANOVA-3 trial met primary endpoint, demonstrating statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic cancer Novocure (NASDAQ:NVCR) today reported financial results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tu

      2/27/25 7:00:00 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care

    $NVCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NovoCure upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded NovoCure from In-line to Outperform and set a new price target of $30.00 from $18.00 previously

      12/2/24 6:59:42 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • NovoCure upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded NovoCure from Neutral to Buy and set a new price target of $30.00 from $24.00 previously

      10/16/24 7:29:57 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • JP Morgan resumed coverage on NovoCure with a new price target

      JP Morgan resumed coverage of NovoCure with a rating of Neutral and set a new price target of $15.00

      11/20/23 7:51:08 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care

    $NVCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Novocure Appoints Christoph Brackmann as Chief Financial Officer

      Novocure (NASDAQ:NVCR) announced today that Christoph Brackmann has been appointed as the company's next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO. Mr. Brackmann joins Novocure from Moderna, Inc. where he served as Senior Vice President of Finance since 2019. While at Moderna he established and built the finance team and oversaw the rapid expansion of the organization during the COVID-19 pandemic. "The addition of Christoph to our Novocure executive team comes at a pivotal time for the organization as we expand our product

      10/30/24 7:02:00 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

      Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns

      10/18/24 9:00:00 AM ET
      $ENV
      $LH
      $MASI
      $MSCI
      Business Services
      Consumer Discretionary
      Medical Specialities
      Health Care
    • Novocure Announces Planned CEO Transition

      After 22 years as CEO, Asaf Danziger to retire at year end, will be succeeded by current CFO Ashley Cordova Wilco Groenhuysen to step down after 12 years as COO, Mukund Paravasthu current Senior Vice President, Product Development to transition to COO Novocure (NASDAQ:NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure's Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company's next CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903420700/en/Asaf Danziger, Chief Executive Officer (Photo: Business Wire) Mr. Danziger, who has served a

      9/3/24 7:00:00 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care

    $NVCR
    SEC Filings

    See more
    • NovoCure Limited filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - NovoCure Ltd (0001645113) (Filer)

      6/6/25 4:26:53 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • NovoCure Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NovoCure Ltd (0001645113) (Filer)

      6/2/25 6:05:55 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • NovoCure Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NovoCure Ltd (0001645113) (Filer)

      4/24/25 7:02:25 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care

    $NVCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NovoCure Limited

      SC 13G/A - NovoCure Ltd (0001645113) (Subject)

      7/10/24 1:14:41 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by NovoCure Limited

      SC 13G/A - NovoCure Ltd (0001645113) (Subject)

      7/8/24 4:32:39 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by NovoCure Limited (Amendment)

      SC 13G/A - NovoCure Ltd (0001645113) (Subject)

      2/13/24 5:09:51 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care

    $NVCR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 18, 2024 - FDA Roundup: October 18, 2024

      For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

      10/18/24 4:16:25 PM ET
      $NVCR
      $BAX
      Medical/Dental Instruments
      Health Care

    $NVCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Leung Gabriel was granted 11,215 units of Ordinary Shares, increasing direct ownership by 14% to 92,444 units (SEC Form 4)

      4 - NovoCure Ltd (0001645113) (Issuer)

      6/6/25 4:21:51 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • Director Stafford Kristin was granted 11,215 units of Ordinary Shares, increasing direct ownership by 367% to 14,269 units (SEC Form 4)

      4 - NovoCure Ltd (0001645113) (Issuer)

      6/6/25 4:20:45 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Madden Martin J.

      4 - NovoCure Ltd (0001645113) (Issuer)

      6/6/25 4:19:11 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care